HGF and glioblastoma: Rilotumumab, a fully human IgG2 anti-hepatocyte growth factor (HGF) mAb, preventing activation of the c-Met receptor and tumor cell growth was not associated with significant antitumor activity in patients with recurrent glioblastoma in a phase II study [138].